The biosimilar approval process: how different is it
Over one year, liraglutide did not significantly improve the primary endpoint (change in cerebral glucose metabolic rate in certain brain regions), but secondary endpointsincluding brain volume loss, and cognitive measuresshowed benefit: ~50% less loss in several brain regions compared to placebo
L- , , - ,
Chronic stress elevates cortisol and inflammatory markers that worsen cardiovascular risk
Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, Ferraro B, Canestrari F, Baldelli AM, De Caetano A, Giordani P, Testa E, Lai V
Are there Problems with Prescribing Compounded Versions of Semaglutide or Tirzepatide